The effect of ganglioside combined with edaravone on the treatment of patients with acute cerebral infarction / 中国基层医药

ABSTRACT

Objective To evaluate the clinical efficacy of ganglioside combined with edaravone in the treatment patients with acute cerebral infarction,to assess the improvement of neurological function and prognosis.To provide the evidence for the clinical treatment of acute cerebral infarction.Methods 126 patients with acute cerebral infarction were selected.According to the digital table,they were randomly divided into the control and the study group,with 65 cases in each group.The control group was given edaravone based on the conventional treatment,the study group was treated with ganglioside and edaravone.The treatment effect was assessed,and the National Institutes of Health Stroke Scale(NIHSS),Fugl -Meyer motor function score,Barthel Index(BI)to assess the improvement of the situation neurological,physical function and daily life were applied.Results The total effective rate of the study group was 82.54%,which was higher than 71.43% of the control group,the difference was statistically significant(χ2 =9.63, P <0.05).The NIHSS score of the study group after treatment was (24.60 ±5.81 )points,which was lower than (27.74 ±5.93)points of the control group,the difference was statistically significant(t =9.97,P <0.05).The FM and BI scores of the study group after treatment were (78.62 ±8.46)points and (72.89 ±8.03)points,which were higher than (73.58 ±8.09)points and (68.30 ±7.45)points of the control group,the differences were statistically significant(t =10.16,11.42,all P <0.05).Conclusion It has better clinical effect on ganglioside and edaravone for the patients with acute cerebral infarction,which can significantly improve neurological function and limb motor function,and significantly improved prognosis of patients.